Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oncaspar

- PMLiVE

AZ buoyed by latest lung cancer data at ESMO

Data from separate Tagrisso and Imfinzi trials show superior PFS among patients

Bristol-Myers Squibb (BMS) building

BMS’ Opdivo and Yervoy ace kidney cancer trial

Combined checkpoint inhibitors show improved survival versus standard therapy

- PMLiVE

Dismay as NICE turns down first-line use of AZ’s Faslodex

Says evidence isn’t convincing for use in post-menopausal women

- PMLiVE

Lynparza approval sets up tighter bout with PARP rivals

US regulator gives AZ the go-ahead for a new maintenance indication and formulation

Bristol-Myers Squibb (BMS) building

BMS data add to checkpoint inhibitor combo confusion

Opdivo and Yervoy meet one objective but miss another in CheckMate-214

- PMLiVE

Biotecnol taps into Cancer Research UK network for first trial

New drug hoped to have broad activity across multiple tumour types

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

- PMLiVE

SMC gives green light for Amgen’s Kyprolis

The committee also gives verdict on three other products

AZ and Medimmune bolsters immuno-oncology leadership

Dr Jean-Charles Soria and Dr Geoffrey Kim join the company

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

- PMLiVE

BMS and Clovis join forces in PARP combo race

Duo will combine Opdivo and Rubraca in phase II and III trials to treat a variety of tumours

AstraZeneca AZ

After MYSTIC setback, FDA gives some comfort to AZ

Awards its PD-L1 inhibitor Imfinzi breakthrough status in locally-advanced NSCLC

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links